Eli Samaha Sells 37,799 Shares of Theravance Biopharma (NASDAQ:TBPH) Stock

Posted by Geri Gentry on Jul 1st, 2026

Theravance Biopharma, Inc. (NASDAQ:TBPH – Get Free Report) major shareholder Eli Samaha sold 37,799 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $17.00, for a total value of $642,583.00. Following the transaction, the insider directly owned 9,174,453 shares of the company’s stock, valued at approximately $155,965,701. The trade was a 0.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Eli Samaha also recently made the following trade(s):

On Tuesday, June 30th, Eli Samaha sold 25,027 shares of Theravance Biopharma stock. The stock was sold at an average price of $17.13, for a total value of $428,712.51.
On Monday, June 29th, Eli Samaha sold 273,871 shares of Theravance Biopharma stock. The stock was sold at an average price of $17.23, for a total value of $4,718,797.33.

Theravance Biopharma Trading Down 0.1%

NASDAQ TBPH traded down $0.02 during trading hours on Wednesday, reaching $16.98. The company had a trading volume of 1,319,960 shares, compared to its average volume of 689,283. The stock has a market capitalization of $875.32 million, a P/E ratio of 7.72 and a beta of 0.17. The stock has a 50-day moving average of $16.56 and a 200 day moving average of $17.29. Theravance Biopharma, Inc. has a 1-year low of $10.82 and a 1-year high of $21.03.

Theravance Biopharma (NASDAQ:TBPH – Get Free Report) last released its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. The company had revenue of $17.70 million during the quarter. As a group, sell-side analysts predict that Theravance Biopharma, Inc. will post 1.54 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership acquired a new position in Theravance Biopharma during the third quarter worth approximately $10,611,000. Pacer Advisors Inc. purchased a new stake in Theravance Biopharma in the 4th quarter valued at $6,342,000. Janus Henderson Group PLC boosted its stake in Theravance Biopharma by 214.8% during the 4th quarter. Janus Henderson Group PLC now owns 400,496 shares of the biopharmaceutical company’s stock worth $7,493,000 after purchasing an additional 273,288 shares during the period. Two Sigma Investments LP boosted its stake in Theravance Biopharma by 1,199.9% during the 3rd quarter. Two Sigma Investments LP now owns 231,272 shares of the biopharmaceutical company’s stock worth $3,377,000 after purchasing an additional 213,480 shares during the period. Finally, HRT Financial LP grew its position in Theravance Biopharma by 892.8% during the 4th quarter. HRT Financial LP now owns 232,852 shares of the biopharmaceutical company’s stock worth $4,356,000 after purchasing an additional 209,397 shares during the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on TBPH. Zacks Research lowered shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, June 8th. Oppenheimer downgraded shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 5th. JonesTrading lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Monday. Wall Street Zen cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, BTIG Research downgraded shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a research note on Monday. One analyst has rated the stock with a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat.com, Theravance Biopharma presently has an average rating of “Hold” and a consensus target price of $21.40.

Read Our Latest Analysis on TBPH

About Theravance Biopharma

(Get Free Report)

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.